Table 2 Volumetric and functional measurements
From: Le Cœur en Sabot: shape associations with adverse events in repaired tetralogy of Fallot
All patients (n = 192) | Adverse outcome (n = 16) | No adverse outcome (n = 176) | |
|---|---|---|---|
DBP [mmHg] | 64.1 ± 10.2 | 65.0 ± 11.3 | 64.0 ± 10.1 |
SBP [mmHg] | 118.0 ± 14.4 | 117.4 ± 15.5 | 118.0 ± 14.3 |
QRS duration (ms) | 147.2 ± 22.8 | 145.1 ± 30.6 | 147.4 ± 21.9 |
LVEDVI [ml/m2] | 88.1 ± 18.2 | 101.3 ± 31.5 | 86.9 ± 15.8 |
LVESVI [ml/m2] | 42.9 ± 14.8 | 53.5 ± 30.9 | 42.0 ± 12.1 |
LV SVI [ml/m2] | 45.3 ± 9.1 | 47.7 ± 10.2 | 45.0 ± 8.9 |
LVEF [%] | 52 ± 8 | 49 ± 10 | 52 ± 8 |
RVEDVI [ml/m2] | 131.4 ± 33.3 | 138.4 ± 31.7 | 130.7 ± 33.3 |
RVESVI [ml/m2] | 83.7 ± 25.7 | 94.7 ± 26.2 | 82.8 ± 25.5 |
RV SVI [ml/m2] | 47.7 ± 15.2 | 43.9 ± 14.8 | 48.0 ± 15.2 |
RVEF [%] | 37 ± 9 | 32 ± 9 | 37 ± 9* |
LVMI [g/m2] | 67.6 ± 12.2 | 77.0 ± 18.0 | 66.7 ± 11.0* |
LV ED MVR [g/ml] | 0.77 ± 0.12 | 0.78 ± 0.1 | 0.78 ± 0.12 |
LV ES MVR [g/ml] | 1.40 ± 0.28 | 1.38 ± 0.33 | 1.41 ± 0.27 |